BiondVax Pharmaceuticals Ltd. (BVXV) , an innovative biopharmaceutical company, announced that patent protection for the company’s main patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccine family was granted in Korea. With patent protection already granted in the US, Europe, Japan, Hong Kong, Australia, China, Russia and Mexico, this latest approval further strengthens BiondVax's intellectual property in international markets.
The Multimeric Multi-Epitope Polypeptide Influenza Vaccines are a family of patents for vaccination against influenza in humans, and specifically vaccines that confer long-lasting protection against multiple and differing flu strains, including both seasonal and pandemic flu strains. The Korean Intellectual Property Office accepted BiondVax's claims for M-001, the company’s universal flu vaccine, and similar polypeptides.
"Asia has been the site of the start of many recent bird-flu pandemics, including H5N1 and H7N9,” said Ron Babecoff, CEO of BiondVax. “Our new patent approval in Korea provides us with an opportunity to establish a strategic partnership in this market. This will enable us to offer local health authorities and governments our pandemic preparedness plan, with the establishment of national stockpiles against all types of influenza pandemics.”
A Step Forward in Fighting Lethal Flu Strains
According to the Centers for Disease Control and Prevention, the flu kills an estimated 36,000 people a year in the United States. Most deaths caused by complications due to influenza typically occur in those who have underlying illnesses or a weakened immune system. BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
In recent months, BiondVax has reported a number of significant milestones. In September, the company presented at the Rodman & Renshaw 17th Annual Global Investment Conference in New York. Also, in preparation for phase 3 clinical trials, BiondVax designated Cytovance Biologics Inc. for the production of clinical batches of M-001 in October.
It can be startling to learnthat influenza remains a potentially fatal virus in the modern age. However, the flu leaves millions around the world vulnerable to other life-threatening infections. BiondVax and its innovative patents has the potential to save lives. “We are encouraged because we are nearing the finishing line when we expect our vaccine will become commercially available for people who need it in the US and worldwide, said Babecoff."
For more information about BiondVax, visit www.biondvax.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer